References
- Pratt C B, Horowitz M, Meyer W. Phase II trial of ifosfamide (ifos) with mesna in patients with pediatric malignant solid tumours. Proc Am Soc Clin Oncol 1985; 4: 234, abstract
- Otten J, Flamant F, Rodary C. Effectiveness of combination ifosfamide, vincristine and actinomycin D in inducing remission in rhabdomyosarcoma in children. Proc Am Soc Clin Oncol 1985; 4: 236, abstract
- Meanwell C A, Blake A E, Kelly K A. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815–819
- Brade W P, Herdrich K, Varini M. Ifosfamide—pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1–47
- McCallum A K. Ifosfamide/mesna encephalopathy. Lancet 1987; 1: 987, letter
- Meanwell C A, Blake A E, Blackledge G. Encephalopathy associated with ifosfamide/mesna therapy. Lancet 1985; 1: 406–407, letter
- Cantwell B MJ, Harris A L, Blackledge G. Ifosfamide/mesna and encephalopathy. Lancet 1985; 1: 752, letter
- Pratt C B, Green A A, Horowitz M E. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986; 4: 1253–1261
- Goren M P, Wright R K, Pratt C B, Pell F E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; 2: 1219–1220, letter
- Pinkerton R, Philip T, Brunat Mentigny M. Ifosfamide, mesna and encephalopathy. Lancet 1985; 1: 1399, letter
- Salloum E, Flamant F, Ghosn M. Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 1987; 5: 1303–1304, letter